重组人内皮抑素治疗晚期肺鳞状细胞癌
[Recombinant Human Endostatin in the Treatment of Advanced Lung Squamous Cell Carcinoma].
作者信息
Xing Puyuan, Hao Xuezhi, Hu Xingsheng, Wang Yan, Li Junling
机构信息
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
出版信息
Zhongguo Fei Ai Za Zhi. 2016 Oct 20;19(10):670-674. doi: 10.3779/j.issn.1009-3419.2016.10.06.
BACKGROUND
Squamous cell carcinoma (SCC) is a common pathological type of non-small cell lung cancer, and advanced lung SCC is incurable. Chemotherapy combined with anti-angiogenesis agents can prolong the patients' survival time. The aim of the study was to analyze the efficacy and safety of recombinant human endostatin (Endostar) in treating advanced lung SCC.
METHODS
We retrospectively analyzed the short-term efficacy and toxicity of recombinant human endostatin combined with traditional chemotherapy regimens in treating 15 advanced lung squamous cell carcinoma patients in Department of Medical Oncology retrospectively, Cancer Hospital, Chinese Academy of Medical Sciences from November 2011 to May 2015. Treatment-related survival was also analyzed.
RESULTS
Among the evaluble 14 patients, the best overall response was partial response in 5 patients (35.7%), stable disease in 7 patients (50.0%), and progressive disease in 2 patients (14.3%). The objective response rate (ORR) was 35.7%, and disease control rate (DCR) was 85.7%. The median progression-free survival (PFS) was 9.3 months. The main grade 3 toxicity was neutropenia (2/15, 13.3%) and vomitting (1/15, 6.7%).
CONCLUSIONS
Chemotherapy combined with recombinant human endostatin enabled good objective response in advanced SCC patients and had well security.
背景
鳞状细胞癌（SCC）是非小细胞肺癌常见的病理类型，晚期肺鳞癌无法治愈。化疗联合抗血管生成药物可延长患者生存时间。本研究旨在分析重组人血管内皮抑素（恩度）治疗晚期肺鳞癌的疗效和安全性。
方法
回顾性分析2011年11月至2015年5月中国医学科学院肿瘤医院肿瘤内科15例晚期肺鳞癌患者采用重组人血管内皮抑素联合传统化疗方案的近期疗效及毒性反应，并分析治疗相关的生存情况。
结果
14例可评价患者中，最佳总体反应为部分缓解5例（35.7%），病情稳定7例（50.0%），疾病进展2例（14.3%）。客观缓解率（ORR）为35.7%，疾病控制率（DCR）为85.7%。中位无进展生存期（PFS）为9.3个月。主要3级毒性反应为中性粒细胞减少（2/15，13.3%）和呕吐（1/15，6.7%）。
结论
化疗联合重组人血管内皮抑素可使晚期肺鳞癌患者获得较好的客观反应，且安全性良好。
Zotero 插件